{"id":"ustekinumab-iv","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Ustekinumab binds to the p40 subunit shared by IL-12 and IL-23, preventing these cytokines from activating T cells and other immune cells that drive inflammation. By inhibiting these pathways, it reduces pathogenic Th1 and Th17 cell responses implicated in autoimmune and inflammatory diseases. This mechanism has proven effective in conditions like psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.","oneSentence":"Ustekinumab is a monoclonal antibody that blocks the IL-12 and IL-23 cytokines, which are key drivers of immune-mediated inflammatory responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:36.578Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"},{"name":"Psoriatic arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"}]},"trialDetails":[{"nctId":"NCT06045754","phase":"PHASE4","title":"A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-04-18","conditions":"Crohn's Disease","enrollment":100},{"nctId":"NCT07310095","phase":"PHASE4","title":"A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)","status":"RECRUITING","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2025-12-30","conditions":"Crohn Disease","enrollment":78},{"nctId":"NCT03466411","phase":"PHASE2, PHASE3","title":"A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-13","conditions":"Crohn's Disease","enrollment":1409},{"nctId":"NCT07444060","phase":"","title":"Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-01","conditions":"CD - Crohn's Disease, Stricture; Bowel, IBD - Inflammatory Bowel Disease","enrollment":100},{"nctId":"NCT05387031","phase":"","title":"Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-08-01","conditions":"Crohn Disease, Stricture; Bowel, Intestinal Stricture","enrollment":239},{"nctId":"NCT04572815","phase":"PHASE2","title":"Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-05-14","conditions":"Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm","enrollment":116},{"nctId":"NCT04232553","phase":"PHASE3","title":"A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-06-22","conditions":"Crohn's Disease","enrollment":996},{"nctId":"NCT04673357","phase":"PHASE3","title":"A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-04-06","conditions":"Crohn Disease","enrollment":101},{"nctId":"NCT05029921","phase":"PHASE4","title":"A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-12-10","conditions":"Crohn Disease","enrollment":182},{"nctId":"NCT07149467","phase":"PHASE3","title":"Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled Study","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-09-10","conditions":"Crohn's Disease Aggravated, Crohn's Disease in Remission","enrollment":454},{"nctId":"NCT03358706","phase":"PHASE1","title":"A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-02","conditions":"Crohn Disease, Ulcerative Colitis","enrollment":28},{"nctId":"NCT04524611","phase":"PHASE3","title":"Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-09-30","conditions":"Crohn's Disease (CD)","enrollment":527},{"nctId":"NCT04630028","phase":"PHASE3","title":"A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-17","conditions":"Colitis, Ulcerative","enrollment":112},{"nctId":"NCT05928039","phase":"PHASE4","title":"PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2023-10-25","conditions":"Crohn Disease","enrollment":297},{"nctId":"NCT03981744","phase":"PHASE3","title":"A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments","status":"TERMINATED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2019-07-26","conditions":"Polymyositis, Dermatomyositis","enrollment":51},{"nctId":"NCT03782376","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2018-12-20","conditions":"Crohn Disease","enrollment":215},{"nctId":"NCT03517722","phase":"PHASE3","title":"A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-16","conditions":"Lupus Erythematosus, Systemic","enrollment":516},{"nctId":"NCT03464136","phase":"PHASE3","title":"Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2018-03-29","conditions":"Crohn Disease","enrollment":386},{"nctId":"NCT04882072","phase":"PHASE3","title":"A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)","status":"TERMINATED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-09-15","conditions":"Takayasu Arteritis","enrollment":14},{"nctId":"NCT02407236","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-07-10","conditions":"Colitis, Ulcerative, Inflammatory Bowel Diseases","enrollment":961},{"nctId":"NCT03107793","phase":"PHASE3","title":"Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2017-04-19","conditions":"Crohn Disease","enrollment":500},{"nctId":"NCT02968108","phase":"PHASE1","title":"A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-01-18","conditions":"Crohn Disease","enrollment":45},{"nctId":"NCT01369355","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-09-13","conditions":"Crohn's Disease, Colitis, IBD","enrollment":1282},{"nctId":"NCT04030533","phase":"PHASE1","title":"Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-11-29","conditions":"Healthy","enrollment":60},{"nctId":"NCT04060888","phase":"PHASE3","title":"A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2020-07-14","conditions":"Lupus Erythematosus, Systemic","enrollment":""},{"nctId":"NCT03362736","phase":"","title":"An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease","status":"NO_LONGER_AVAILABLE","sponsor":"Janssen Research & Development, LLC","startDate":"","conditions":"Crohn Disease","enrollment":""},{"nctId":"NCT06786507","phase":"","title":"A Direct Head-to-head Comparison of Ustekinumab with Infliximab for the Treatment of Ulcerative Colitis","status":"NOT_YET_RECRUITING","sponsor":"Helwan University","startDate":"2025-05-15","conditions":"Ulcerative Colitis (UC)","enrollment":100},{"nctId":"NCT03926130","phase":"PHASE3","title":"A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-07-23","conditions":"Crohn's Disease","enrollment":1158},{"nctId":"NCT04089345","phase":"PHASE3","title":"Stelara fOr ChRonic AntibioTic rEfractory pouchitiS","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2020-06-15","conditions":"Pouchitis","enrollment":20},{"nctId":"NCT05169593","phase":"PHASE4","title":"Prevention of Postoperative Endoscopic Recurrence with Endoscopy-driven Versus Systematic Biological Therapy","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2022-09-08","conditions":"Crohn Disease","enrollment":292},{"nctId":"NCT04629196","phase":"PHASE4","title":"Induction Optimization With Stelara for Crohn's Disease","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2022-02-16","conditions":"Crohn Disease","enrollment":12},{"nctId":"NCT02911116","phase":"PHASE2","title":"Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2017-03-30","conditions":"Uveitis","enrollment":8},{"nctId":"NCT02349061","phase":"PHASE2","title":"A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-15","conditions":"Lupus Erythematosus, Systemic","enrollment":102},{"nctId":"NCT02187172","phase":"PHASE4","title":"Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2014-07","conditions":"Psoriasis, Cardiovascular Disease","enrollment":43},{"nctId":"NCT01369342","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-07","conditions":"Crohn's Disease, Inflammatory Bowel Disease, IBD","enrollment":640},{"nctId":"NCT00320216","phase":"PHASE2","title":"A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2003-11","conditions":"Psoriasis","enrollment":320},{"nctId":"NCT00265122","phase":"PHASE2","title":"A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2004-04","conditions":"Crohn Disease","enrollment":131},{"nctId":"NCT00771667","phase":"PHASE2","title":"A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2008-12","conditions":"Crohn's Disease","enrollment":526}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":64,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["STELARA"],"phase":"phase_3","status":"active","brandName":"Ustekinumab IV","genericName":"Ustekinumab IV","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ustekinumab is a monoclonal antibody that blocks the IL-12 and IL-23 cytokines, which are key drivers of immune-mediated inflammatory responses. Used for Moderate to severe plaque psoriasis, Psoriatic arthritis, Crohn's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}